London site

Discussion in 'Merck' started by anonymous, Oct 22, 2017 at 11:50 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Merck opening R&D in UK again. Hope we got 10 year lease on building to get out easy during 2027 reorg when slash and burn strategy is popular again for boosting bottom line. Will new site be called Sterling Park?

    When next clinical trial fails and drug goes off patent layoff more from hard working sites while telling us how important/better these new sites are that will never deliver shit for 30 years. But we need to be where the smart people are! You know because smart people only want to live in regions where a studio apartment is $1M and the family has to live on cat food to make ends meet. Fancy Feast tonight y’all!

    Merck obsessed with putting out an image of hip and innovative with nothing to back it up. Can’t attract or retain talent AT ALL LEVELS!! Workforce suicidal from constant change. Wasting $$$ trying to buy image now then F everyone later when it results in nothingggggggg. Social media campaign of Russian espionage proportions can’t make a corpse look attractive.

    What’s that? Another merger in sight? Ahh some fuel for the new smarty sites. Pass the happy pills!
     

  2. anonymous

    anonymous Guest

    http://www.msd-uk.com/static/pdf/MSD%20press%20statement-Jewel%20announcement.pdf

    https://www.fiercebiotech.com/biotech/merck-places-ps1b-bet-r-d-post-brexit-britain

    In total, the site will employ 950 people, although only 150 of the positions will be new research roles. The remaining 800 staff will perform tasks handled today at existing Merck buildings in the U.K.—which the Big Pharma is leasing, having sold the site to the CRO Pharmaron—and functions aimed at the domestic market.

    Coupled to the size of Merck’s investment—which the Financial Times puts at £1 billion—the timing of the news makes it arguably more critical for the government and perceptions of the future of U.K. life sciences than facilities planned by firms including Alnylam and Novo Nordisk.
     
  3. anonymous

    anonymous Guest

    Stop it. It's been planned for a while. You are just bitter R&D will be eliminated in NJ. That has also been planned for a while. NJ is the odd man out. Massachusetts, California, UK and China will be R&D. That is where the best scientists are. It's the only chance we have to rebuild the pipeline. Have you been living in a cave or what?
     
  4. anonymous

    anonymous Guest

    Rahway will survive as CMC center. West Point however is dead man walking however slowly.
     
  5. anonymous

    anonymous Guest

    cheerio! time for the final death blow to the legacy sites (KW,RY,WP)
     
  6. anonymous

    anonymous Guest

    tick-tock
     
  7. anonymous

    anonymous Guest

    Way to build pipeline is to simultaneously start 3 new sites and dismantle legacy sites? k. New sites haven’t even got first electric bill yet, but are filling pipeline now?
     
  8. anonymous

    anonymous Guest

    Best scientist? By what measure? Best at 5S maybe but that's all.
     
  9. anonymous

    anonymous Guest

    Agreed. Boston site took 10yr to deliver first drug candidate. San Francisco and Cambridge sites on track to deliver first pizzas to surrounding drug companies by 2028. But good getaway spots for management to make frequent trips to while scouting licensing opportunities under disguise of networking.